Ealixir, Inc.
Ealixir, Inc. (EAXR) Financial Performance & Income Statement Overview
Explore the financials of Ealixir, Inc. (EAXR), including yearly and quarterly data on income, cash flow, and balance sheets.
Ealixir, Inc. (EAXR) Income Statement & Financial Overview
Review Ealixir, Inc. EAXR income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q2 2025 | Q4 2024 |
|---|---|---|---|
| Revenue | $675525.00 | $1.16M | $278736.00 |
| Cost of Revenue | $675525.00 | $94775.00 | $179963.00 |
| Gross Profit | $0.00 | $1.07M | $98773.00 |
| Gross Profit Ratio | $0.00 | $0.92 | $0.35 |
| R&D Expenses | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $764823.00 | $1.02M | $848320.00 |
| Operating Expenses | $764823.00 | $1.02M | $848320.00 |
| Total Costs & Expenses | -$786516.00 | $1.02M | $1.03M |
| Interest Income | $0.00 | $0.00 | $0.00 |
| Interest Expense | $6614.00 | $6845.00 | $4191.00 |
| Depreciation & Amortization | $21693.00 | $21073.00 | $40582.00 |
| EBITDA | $426194.00 | $67250.00 | -$708965.00 |
| EBITDA Ratio | $0.63 | $0.06 | -$2.54 |
| Operating Income | -$110991.00 | $47224.00 | -$749547.00 |
| Operating Income Ratio | -$0.16 | $0.04 | -$2.69 |
| Other Income/Expenses (Net) | $637684.00 | $33882.00 | -$4191.00 |
| Income Before Tax | $526693.00 | $81106.00 | -$753738.00 |
| Income Before Tax Ratio | $0.78 | $0.07 | -$2.70 |
| Income Tax Expense | $73096.00 | $80824.00 | -$92857.00 |
| Net Income | $453597.00 | $282.00 | -$660881.00 |
| Net Income Ratio | $0.67 | $0.00 | -$2.37 |
| EPS | $0.007 | $0.00 | -$0.01 |
| Diluted EPS | $0.007 | $0.00 | -$0.01 |
| Weighted Avg Shares Outstanding | $60.28M | $60.28M | $60.28M |
| Weighted Avg Shares Outstanding (Diluted) | $60.28M | $60.28M | $60.28M |
The company's financials show resilient growth, with revenue advancing from $278736.00 in Q4 2024 to $1.16M in Q2 2025. Gross profit remained healthy with margins at 92% in Q2 2025 compared to 35% in Q4 2024. Operating income hit $47224.00 last quarter, sustaining a consistent 4% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $67250.00. Net income dropped to $282.00, while earnings per share reached $0.00. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan